Single-Use Bioreactors Market is Powered by Increasing Number of Collaborations

The single-use bioreactors market was USD 3,432.4 million in 2022, which will touch USD 13,595.9 million by 2030, powering at a rate of 18.8% by the end of this decade. This is credited to the increasing requirement for biologic and biosimilar drugs because of the growing occurrence of communicable and chronic diseases, and the obtainability of pioneering single-use bioreactors. 

Based on product type, the system category is the leader of the industry, with a share of 55% in 2022. This is credited to the widespread use of such systems in biopharma manufacturing facilities needing a high yield of products. Moreover, such systems are cost-effective, adaptable, and possess significant production capabilities.  

Furthermore, there is a growing need for fast expansion of biotherapeutics, for example hormones, vaccines, antibodies, and enzymes, in large measures, which can be formed in such bioreactors. Consequently, all these factors are driving the development of the industry in this category. 

Single-Use Bioreactors Market

Based on the type segment, stirred-tank bioreactors had the largest share, of 45%. This is because of the many advantages offered by them for example low functioning costs, good fluid mixing aptitude and oxygen transfer, and effortless scale-up. 

While, the wave-induced category will grow significantly in the future. This can be credited to the manufacturing expansions in this type of system. Also, advantages such as flexible arrangement of accessories, suitable handling, low costs, and long-life cycle are impacting the market positively. 

Based on the cell type segment, the mammalian cells were the leader of the industry. This is because these cells are extensively used for the expansion of recombinant proteins and biopharma therapies. As per a study, it has been observed that a large amount of biopharma candidates is advanced with the use of the mammalian cell culture. 

While, the yeast cells will grow significantly in the future. This can be for the reason that these cells provide advantages in the production of therapeutic recombinants and aid in serving as homologous and heterologous hosts for biopharma synthesis. 

North America is the leader of the single-use bioreactors market. This is credited to the rising occurrence of chronic disorders such as diabetes, the existence of top players and strong healthcare facilities, tech progressions in this field, and robust R&D initiatives for example availability and accessibility to research funding, in the region. 

The U.S. is contributing to the expansion of the industry. This is ascribed to the rising acceptance of pioneering technologies, the growing public consciousness for ailment prevention, robust government support, and cutting-edge healthcare amenities in the nation. 

It is because of the increasing count of collaborations among companies’ allover the world, the demand for single-use bioreactors is on the rise. 

SOURCE: P&S Intelligence